Categories: NewsPharmaceutical

Protagonist Therapeutics Reports Granting of Inducement Award

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

NEWARK, CA / ACCESSWIRE / July 18, 2023 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on July 17, 2023, it issued inducement awards to Peter Morello, Ph.D. the Company’s recently hired Vice President, Medical Communications and Publication Planning, in accordance with the terms of Dr. Morello’s employment offer letter. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.

Dr. Morello received options to purchase 40,000 shares of Protagonist Therapeutics common stock. The exercise price of the options is $21.11, which was the per-share closing price of Protagonist Therapeutics common stock on the Nasdaq Global Market on July 17, 2023. The shares subject to the option vest over a four-year period, with 25 percent of the shares subject to the option vesting on the first anniversary of Dr. Morello’s date of hire and the remainder vesting in equal monthly installments over three years thereafter. The awards were approved by the compensation committee of the Company’s board of directors and were granted as a material inducement to Dr. Morello’s entering into employment with the Company in accordance with Nasdaq Marketplace Rule 5635(c)(4).

About Protagonist Therapeutics

Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities rusfertide and JNJ-2113 (formerly PN-235) in advanced stages of clinical development, both derived from the Company’s proprietary technology platform. Protagonist scientists jointly discovered PN-235 (now known as JNJ-2113) as part of Protagonist’s IL-23R collaboration with Janssen and followed it through IND-enabling pre-clinical and Phase 1 studies, with Janssen assuming responsibility for further clinical development. Rusfertide, a mimetic of the natural hormone hepcidin, is the Company’s lead drug candidate currently in a global Phase 3 stage of development. The Phase 2 REVIVE study is now complete, with an open-label extension underway. The global Phase 3 VERIFY study of rusfertide in polycythemia vera is ongoing. Protagonist retains all worldwide development and commercialization rights to rusfertide.

Protagonist is headquartered in Newark, California. For more information on Protagonist, please visit the Company’s website at www.protagonist-inc.com.

Contact
Jami Taylor
Email: j.taylor@ptgx-inc.com

SOURCE: Protagonist Therapeutics, Inc.

View source version on accesswire.com:
https://www.accesswire.com/768496/Protagonist-Therapeutics-Reports-Granting-of-Inducement-Award

Staff

Recent Posts

Santiam Hospital and Clinics enters into Prime Vendor agreement with Medline

Oregon-based hospital taps into Medline's custom pack capabilities and distribution services NORTHFIELD Ill., June 9,…

4 hours ago

20/20NOW Advances Tele-Optometry with New VP of Professional Services Dr. Noelle Tchang OD and Spotlights Telehealth at Digital EyeCon

HOLBROOK, N.Y., June 9, 2025 /PRNewswire/ -- 20/20NOW, a pioneer in ocular telehealth, proudly announces…

4 hours ago

Business Integra Launches Mission-Ready Healthcare Staffing Solutions Backed by AI Technology

BETHESDA, Md., June 9, 2025 /PRNewswire/ -- Business Integra (BI), a leader in mission-critical talent solutions,…

4 hours ago

Imre Introduces the AI Conversation Converter

Agency launches First-in-Kind platform to quickly insert healthcare brands directly into the AI conversation NEW…

4 hours ago

Health-E Commerce® expands telehealth offerings with LifeMD™ to provide sleep treatments via FSA Store® and HSA Store®

New collaboration delivers 50% off prescription sleep support for new customers who are struggling with…

10 hours ago